Pear Therapeutics Leadership

Corey M McCann M.D., Ph.D. is the President and CEO of Pear Therapeutics, a company developing Prescription Digital Therapeutics (PDTs) for the treatment of severe medical conditions. Pear aims to redefine medicine by discovering, developing, and delivering clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from FDA. Pear’s lead product, reSET®, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from FDA to treat disease. Pear’s second product, reSET-O®, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear’s third product, Somryst™, for the treatment of chronic insomnia, was the first PDT submitted through FDA’s traditional 510(k) pathway while simultaneously reviewed through FDA’s Software Precertification Pilot Program.Previously, Corey was an investor with MPM Capital, where he evaluated new healthcare investment opportunities, managed relationships with strategic partners, and oversaw strategy and execution at portfolio companies. Prior to MPM, he was an Engagement Manager with McKinsey & Company, where he advised pharmaceutical, medical device, and biotechnology companies on the acquisition, development, and commercialization of life science technologies. Corey has previous investment experience with RiverVest Venture Partners, where he performed diligence on early stage investments, and at NeuroInsights, where he evaluated brain related technologies. Corey is also a co-founder, advisor, or Board Director at multiple healthcare companies including Alcyone Lifesciences, NOUS Imaging, Resolute Bio, Selexys Pharmaceuticals, and Zillion Health. Dr. McCann trained as a physician-scientist via the Medical Scientist Training Program. For his PhD, he studied the molecular biology of synapses at Harvard University and at Washington University in St Louis. He was also a post-doctoral researcher at the Massachusetts General Hospital where he developed imaging techniques for the visualization of the brain. Dr. McCann received his M.D. from Washington University in St. Louis. He graduated summa cum laude from The Pennsylvania State University where he was an Evan Pugh Scholar, receiving a B.S. in Biology with minors in neuroscience, biochemistry, and molecular biology.

Neuroscientist, Virtual Reality, and Digital Health Expert at Stanford University Virtual Human Interaction Lab

Chris is our CFO & COO. Before joining Pear, he served as President & Chief Executive Officer of Cerulean Pharma. He previously served as Cerulean’s Chief Operating Officer and before that as its Senior Vice President and Chief Business Officer. Prior to that, he held a number of senior executive positions at various biopharmaceutical companies, including President & Chief Executive Officer of Alvos Therapeutics, Inc., Chief Business Officer at Hydra Biosciences, Inc., and Senior Vice President, General Counsel and Secretary at Cubist Pharmaceuticals, Inc. Mr. Guiffre has also held several positions at Renaissance Worldwide, Inc., including Vice President, General Counsel and Clerk. Prior to that, he was an Associate at Bingham, Dana & Gould LLP (now known as Morgan, Lewis & Bockius LLP). Mr. Guiffre received a BS from Babson College, a JD from Boston College Law School, and an MBA from Boston College Carroll School of Management.

Decisive, resilient and adaptive global portfolio and product leader and integrator who enjoys blazing new trails with large cross-functional teams to meet bold goals for customers and patients.

Global strategic leader with multi-disciplinary experience managing all functional areas including marketing, product innovation, portfolio strategy and go-to-market execution in positions of increasing leadership responsibility. Proven capability to lead complex businesses to deliver superior results across all product lifecycles. Demonstrated ability to drive business value through innovation (new products, channels, business models and markets), compelling strategies, and building high-performance, diverse teams. Creative, data-driven with high learning agility to initiate and affect business growth and transformation. Strong interpersonal and effective communication skills.

Dr. Maricich is a licensed, board-certified physician-scientist, investor, clinical/therapeutic developer and strategist. He improves our healthcare system by investing in, advising for, & leading innovative firms. He has practiced clinically, caring for patients, as well as lead successful teams+programs at healthcare & biotech (HLS) firms including Xdynia (acquired by Cavion), Cavion (acq by Jazz Pharmaceuticals), Corixa (acq by GlaxoSmithKline), Pear Therapeutics (1st FDA-market authorized, clinically-validated digital therapeutic to treat disease + reSET-O 1st for combo with pharmacotherapy, Somryst for chronic insomnia). He founded a digital health firm as med student that structured clinical data using NLP.

He has worked across, biotech (small-molecules) & investment firms, including therapeutics, leading cloud computing firm, digital health, AI/analytics, delivery, device, and IP law. Dr. Maricich was in Michael Porter’s first Value-Driven Health Care course at Harvard. As a medical student he founded the Pathos Project. He is a published author & frequent speaker.

Dr. Maricich completed his education and training at Harvard University, the University of Washington, the University of Notre Dame, and the University of Virginia.

1) Physician, licensed, and board-certified in Internal Medicine

2) Chief Medical Officer & Head of Dev at Pear Therapeutics: leads the Development + Clinical/Regulatory/Quality/Med Affairs org, including leading reSET's clinical+regulatory activities: the 1st FDA-authorized prescription digital therapeutic to treat disease & pipeline of Therapeutics, includes reSET-O, 1st FDA-authorized PDT used in combo with pharmacotherapy, and Somryst, FDA-authorized for chronic insomnia

3) Investor: Asclepius Capital

4) Founder, Pathos Project, a non-profit

Kathy Jeffery is Chief People Officer of Pear Therapeutics. Kathy has unique experience where she held leadership positions as Vice President of Human Resources at four early stage businesses and two Fortune 500 companies including Recurly, Sportvision, and TNS/WPP. She has worked and consulted with a variety of industries in technology, financial services, media, and professional services companies. With over 20 years of experience in Human Resources and Executive Coaching, Kathy’s knowledge includes change and talent management, culture development, and organization development. Kathy’s approach is to focus on building and sustaining a positive employee experience as well developing a strategic partnership with executives to help scale and support the company vision. Kathy received her MSc in Managerial Communication from Northwestern University and a BA in Liberal Arts with a concentration in Human Resource Management from DePaul University. As a life-long learner she is certified in leadership development and co-active coaching through the Coaches Training Institute.

Corey M McCann M.D., Ph.D. is the President and CEO of Pear Therapeutics, a company developing Prescription Digital Therapeutics (PDTs) for the treatment of severe medical conditions. Pear aims to redefine medicine by discovering, developing, and delivering clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from FDA. Pear’s lead product, reSET®, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from FDA to treat disease. Pear’s second product, reSET-O®, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear’s third product, Somryst™, for the treatment of chronic insomnia, was the first PDT submitted through FDA’s traditional 510(k) pathway while simultaneously reviewed through FDA’s Software Precertification Pilot Program.Previously, Corey was an investor with MPM Capital, where he evaluated new healthcare investment opportunities, managed relationships with strategic partners, and oversaw strategy and execution at portfolio companies. Prior to MPM, he was an Engagement Manager with McKinsey & Company, where he advised pharmaceutical, medical device, and biotechnology companies on the acquisition, development, and commercialization of life science technologies. Corey has previous investment experience with RiverVest Venture Partners, where he performed diligence on early stage investments, and at NeuroInsights, where he evaluated brain related technologies. Corey is also a co-founder, advisor, or Board Director at multiple healthcare companies including Alcyone Lifesciences, NOUS Imaging, Resolute Bio, Selexys Pharmaceuticals, and Zillion Health. Dr. McCann trained as a physician-scientist via the Medical Scientist Training Program. For his PhD, he studied the molecular biology of synapses at Harvard University and at Washington University in St Louis. He was also a post-doctoral researcher at the Massachusetts General Hospital where he developed imaging techniques for the visualization of the brain. Dr. McCann received his M.D. from Washington University in St. Louis. He graduated summa cum laude from The Pennsylvania State University where he was an Evan Pugh Scholar, receiving a B.S. in Biology with minors in neuroscience, biochemistry, and molecular biology.

Neuroscientist, Virtual Reality, and Digital Health Expert at Stanford University Virtual Human Interaction Lab

Corey M McCann M.D., Ph.D. is the President and CEO of Pear Therapeutics, a company developing Prescription Digital Therapeutics (PDTs) for the treatment of severe medical conditions. Pear aims to redefine medicine by discovering, developing, and delivering clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from FDA. Pear’s lead product, reSET®, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from FDA to treat disease. Pear’s second product, reSET-O®, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear’s third product, Somryst™, for the treatment of chronic insomnia, was the first PDT submitted through FDA’s traditional 510(k) pathway while simultaneously reviewed through FDA’s Software Precertification Pilot Program.Previously, Corey was an investor with MPM Capital, where he evaluated new healthcare investment opportunities, managed relationships with strategic partners, and oversaw strategy and execution at portfolio companies. Prior to MPM, he was an Engagement Manager with McKinsey & Company, where he advised pharmaceutical, medical device, and biotechnology companies on the acquisition, development, and commercialization of life science technologies. Corey has previous investment experience with RiverVest Venture Partners, where he performed diligence on early stage investments, and at NeuroInsights, where he evaluated brain related technologies. Corey is also a co-founder, advisor, or Board Director at multiple healthcare companies including Alcyone Lifesciences, NOUS Imaging, Resolute Bio, Selexys Pharmaceuticals, and Zillion Health. Dr. McCann trained as a physician-scientist via the Medical Scientist Training Program. For his PhD, he studied the molecular biology of synapses at Harvard University and at Washington University in St Louis. He was also a post-doctoral researcher at the Massachusetts General Hospital where he developed imaging techniques for the visualization of the brain. Dr. McCann received his M.D. from Washington University in St. Louis. He graduated summa cum laude from The Pennsylvania State University where he was an Evan Pugh Scholar, receiving a B.S. in Biology with minors in neuroscience, biochemistry, and molecular biology.